Location History:
- Cambridge, MA (US) (2017)
- Sierentz, FR (2018 - 2021)
Company Filing History:
3 out of 4 
2 out of 303 
2 out of 444 
Years Active: 2017-2021
Title: The Innovations of Jean-Baptiste Langlois
Introduction
Jean-Baptiste Langlois is a notable inventor based in Sierentz, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds that target specific kinases involved in various disorders. With a total of six patents to his name, Langlois has established himself as a key figure in biomedical research.
Latest Patents
Langlois's latest patents include innovative compounds such as difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines. These compounds serve as inhibitors for phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), and PI3K-related kinase (PIKKs). The invention is particularly useful for treating disorders mediated by lipid kinases. Another significant patent involves a manufacturing process for triazine, pyrimidine, and pyridine derivatives. This method utilizes a type of Suzuki coupling with a pyridyl- or pyrimidinyl-borane, allowing for the production of various nitrogen and carbon-based compounds.
Career Highlights
Throughout his career, Langlois has worked with prominent organizations such as Piqur Therapeutics AG and the Whitehead Institute for Biomedical Research. His work has focused on advancing therapeutic agents that can effectively address complex medical conditions.
Collaborations
Langlois has collaborated with esteemed colleagues, including Paul Hebeisen and Florent Beaufils. These partnerships have contributed to the successful development of his innovative compounds and research initiatives.
Conclusion
Jean-Baptiste Langlois is a distinguished inventor whose work in the pharmaceutical field has led to the creation of valuable therapeutic compounds. His contributions continue to impact the medical research community positively.